A new twist on a decades-old anticancer strategy has shown powerful effects against multiple cancer types in a preclinical study from researchers in the Perelman School of Medicine at the University ...

The American Red Cross officially opened its newest blood and platelet donation center in Brighton. It will serve not only ...

A new twist on a decades-old anticancer strategy has shown powerful effects against multiple cancer types in a preclinical ...

TC BioPharm (NASDAQ: TCBP) , a clinical-stage biotech company, announced plans to initiate Proof of Concept preclinical studies for its lead therapy, ...

Molecular Partners' DARPin platform shows promise, but future funding is uncertain. Learn why MOLN stock could be a risky, ...

The Oncologist explained how environmental toxins can lead to blood cancer. Know the precautionary tips to take.

PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced ...

A new twist on a decades-old anticancer strategy has shown powerful effects against multiple cancer types in a preclinical study from researchers in the Perelman School of Medicine at the University ...

LYT-200 now has gained fast track designation from the FDA in acute myeloid leukemia in addition to its prior designation for ...

在该研究中，陆佩华院长带领团队创新性地采用基于纳米抗体的CD7 CAR-T治疗急性髓系白血病，研究结果不仅在肿瘤杀伤力和安全性上取得了显著进展，更为难治复发急性髓系白血病的治疗开辟了新路径。

Novel CD37 antibody-drug conjugate shows promise in targeting the Achilles’ heel of acute myeloid leukemia cells.

Preliminary fourth quarter 2024 total revenue of approximately $57.6 million which includes TAVALISSE® net product s ...